Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-31
2005-05-31
Trinh, Ba K. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S295000, C549S328000
Reexamination Certificate
active
06900242
ABSTRACT:
Compounds of Formula Ia and Ic having a lactone structure and an methylene group at the alpha-position of the lactone structure and methods for using and making the compounds have been disclosed. The lactone compounds can be reacted with an neucleaphilic agent to open the lactone ring to a compound of Formula Ib. The lactone of Formula Ia and its functional derivatives have been isolated fromSecuridaca virgata. These compounds are referred to as LMSV-6 or Securolide™. The purified compounds have demonstrated activity in assays for anti-bacterial and anti-fungal activities, and for treating proliferation disorders such as cancer. Based on the in vitro assays, the lactones are useful for treating proliferation disorders including, for example, breast cancer, colon cancer, rectal cancer, stomach cancer, pancreatic cancer, lung cancer, liver cancer, ovarian cancer, esophageal cancer, and leukemia. They are also effective for treatment of bacterial and fungal infections, including treatment of peptic ulcer disease, gingivitis and periodontitis. The lactone and its derivatives has the following chemical structure:wherein R1-R9and Y1-Y3taken independently are preferably a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic groups or groupings which optionally include a heteroatom such as oxygen, sulfur, or nitrogen groupings in linear, branched, or cyclic structural formats; Z and X are independently and preferably a heteroatom such as oxygen, sulfur, or nitrogen groupings in linear, branched, or cyclic structural formats; and Z′ may a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic groups or groupings which optionally include a heteroatom such as oxygen, sulfur, or nitrogen groupings in linear, branched, or cyclic structural formats.
REFERENCES:
patent: 4613613 (1986-09-01), Oguri et al.
patent: 5250735 (1993-10-01), Wong et al.
patent: 5281622 (1994-01-01), Wong et al.
patent: 5646164 (1997-07-01), Tzeng et al.
patent: 5905089 (1999-05-01), Hwang et al.
patent: 5962460 (1999-10-01), Tzeng et al.
patent: 6232474 (2001-05-01), Brandenburg et al.
patent: 0 712 843 (1999-11-01), None
patent: 2002-37797 (2002-02-01), None
Grigg, et al., “X=Y-ZH Systems as potential 1,3-dipoles part 35. Generation of nitrones from oximes. Class 3 processes. Tandem intramolecular Michael addition (1,3-azaprotio cyclotransfer)-intermolecular 1-3-dipolar cycloaddition reactions.1,2”Tetrahedron48(33): 6929-6952 (1992).
Chen, et al., “α-Methylene-γ-butyrolactones: synthesis and vasorelaxing activity assay of coumarin, naphthalene, and quinolone derivatives,”Chem. Pharm. Bull. 46(6): 962-965 (1998).
Fuchino, et al., “New sesquiterpene lactones fromElephantopus mollisand their leishmanicidal activities,”Planta Med67: 647-653 (2001).
Huang, et al., “Synthetic and cytotoxic studies at α-methylene-γ-butyrolactone bearing pyrimidines,”Kaohsiung J. Med. Sci.9: 707-711 (1993).
Kuhajda, et al., “Synthesis and antitumor activity of an inhibitor of fatty acid synthase,”Proc. Natl. Acad. Sci. USA97(7): 3450-3454 (2000).
Lee, et al., “Sesquiterpene antitumor agents: inhibitors of cellular metabolism,”Science196: 533-535 (1977).
Lee, et al., “Synthesis and anticancer evaluation of certain α-methylene-γ-(4-substituted phenyl)-g-butyrolactone bearing thymine, uracil, and 5-bromouracil,”Bioorg.&Med. Chem.9: 241-244 (1999).
Maria, et al., “Gastric anti-ulcer activity of several α,β-unsaturated carbonyl compounds in rats,”Biol. Pharm. Bull.23(5): 555-557 (2000).
Panda, et al., “Mechanism of action of alpha-methylene-gamma-lactone derivatives of substituted nucleic acid bases in tumour cells,”Chemotherapy35: 174-180 (1989).
Rodriguez, et al., “Biological activities of sesquiterpene lactones,”Phytochemistry15: 1573-1580 (1976).
Sanyal, et al., “New α-methylene-lactone derivatives of substituted nucleic acid bases as potential anticancer agents,”J. Med. Chem.29(5): 595-599 (1986).
Schlewer, et al., “Synthesis of α-methylene-γ-butyrolactones: a structure-activity relationship study of their allergenic power,”J. Med. Chem.23: 1031-1038 (1980).
Spring, et al., “Annuithrin, a new biologically active germacranolide fromHelianthus annuus,” Phytochemistry20(8): 1883-1885 (1981).
Willuhn, “Amicaflowers: pharmacology, toxicology, and analysis of the sesquiterpene lactones—their main active substance,” inPhytomedicines of Europe: Chemistry and Biological Activity(Lawson, et al, eds.) Washington DC American Chemical Society, pp. 118-132 (1997).
Magnachem International Laboratories, Inc.
Pabst Patent Group LLP
Trinh Ba K.
LandOfFree
Lactone formulations and method of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactone formulations and method of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactone formulations and method of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3441130